The FDA has delayed granting full approval of Novavax's COVID-19 vaccine despite it being on track to be cleared until ...

I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in the U.S.

NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered ...

Tourmaline Bio's Pacibekitug shows promise in IL-6 targeting for autoimmune diseases. Learn about its potential and ongoing trials. Read why TRML is a hold.

Experts discuss survival data from the TiNivo-2 phase 3 trial and practical approaches to dose management in clinical practice.

Solriamfetol is a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT 1A agonist. It is currently approved under the brand name Sunosi ® to improve ...

Following a successful Type B end-of-phase 2 meeting, the FDA has approved the start of a phase 3 trial of linperlisib in peripheral T-cell lymphoma.

The firm believes VVD-159642 has the potential to treat a broad patient population, including those with RAS- and HER2-overexpressed tumors.

Ociperlimab is described as a humanised IgG1 monoclonal antibody with the potential to enhance T cell-mediated immune ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Immune response data from FLAMINGO-01 shows positive results in patients with HER2+ breast cancer, suggesting potential for ...

In response to a request from the European Medicines Agency (EMA) following the death of a 16-year-old patient in the U.S., ...